White House plans new biotech drug pricing deals

The White House is preparing new voluntary drug-pricing agreements with mid-sized biotech firms to lower state Medicaid outpatient drug costs by tying prices to international benchmarks. In exchange, participating companies would receive relief from certain Medicare pilot programs and potential tariff concessions, creating regulatory trade-offs for investors. This expansion follows prior deals with large firms and includes commitments to disclose medication data on a government digital platform. Participation is voluntary for states, and it remains unclear how much savings will reach federal programs or low-income patients. The push is part of the Trump administration’s broader effort to lower U.S. drug prices and encourage manufacturing to return to the United States, signaling a persistent policy focus ahead of elections. Some reports also reference the use of most-favoured-nation pricing deals and tariff relief as bargaining tools in these negotiations.